IL-33/ST2

Molecular target

Interleukin-33 (IL-33), a cytokine, is part of the IL-1 family, and is constitutively expressed by a broad range of cell types, including fibroblasts, epithelial, and endothelial cells, particularly in mucosal tissues.  Following cell stress, tissue injury or necrosis, IL-33 release acts as an alarmin binding to the ST2 receptor and activating cells of lymphoid and myeloid origin. Functionally, ST2 and its ligand, IL-33, regulate inflammatory processes and pathway activation has been associated with diseases including asthma, pulmonary fibrosis and rheumatoid arthritis.

Antibody Tools

AstraZeneca has developed a number of preclinical antibody tools that target the IL-33/ST2 pathway.

 Anti-human
ST2
(Ab1440361)		Mouse anti-ST2 ZY0NP0_E06Human IL-33 TrapMouse IL-33 TrapMouse ST2-Fc
Source/ IsotypeMouse Mouse IgG1Human IgG1Human IgG1Human IgG1
ReactivityHumanMouseHumanMouseMouse
Protein TargetST2, sST2ST2IL-33IL-33IL-33
ApplicationNeutralising

FACS		Neutralising

In vivo		Neutralising

In vitro		Neutralising

In vitro/ In vivo		Neutralising
AntibodyMonoclonalMonoclonalRecombinant proteinRecombinant proteinRecombinant protein
Brief
Description/
Application
info?		In vitro
In vitro / In vivo

30mg/kg		In vitro / In vivo
In vitro / In vivo
In vitro / In vivo
Any other info?In house hybridomaIn house 10.4161/19420862.2014.985489   

Recombinant Proteins

 Human
rIL-33 proteins		Mouse
rIL-33 proteins		Human IL-33 Trap

Mouse IL-33 TrapMouse ST2-Fc
Source/ IsotypeE.coli proteinE.coli protein
Human IgG1Human IgG1Human IgG1
ReactivityHumanMouseHumanMouseMouse
Protein Target112-270 aa wild type

112-270 aa C -> S
Mutant		109-266aa wild type

109-266 aa C -> S
Mutant		IL-33IL-33IL-33
ApplicationIn vitro / In vivoIn vitro / In vivoNeutralising

In vitro/ In vivo		Neutralising

In vitro/ In vivo		Neutralising

In vitro/ In vivo
ProteinRecombinant proteinRecombinant proteinRecombinant proteinRecombinant proteinRecombinant protein<

Back to top